IDEX Biometrics : Presentation Q1 2021

First Quarter 2021 Presentation

May 12, 2021

Disclaimer

This presentation includes forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. Such forward-looking information and statements are based on current expectations, estimates and projections about global economic conditions, the economic conditions of the regions and industries that are major markets for IDEX Biometrics ASA (IDEX) and its subsidiaries. These expectations, estimates and projections are generally identifiable by statements containing words such as

"expects", "believes", "estimates" or similar expressions denoting uncertainty. Important factors that could cause actual results to differ

materially from those expectations include, among others, economic and market conditions in the geographic areas and industries that are or will be markets we target, market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates, and such other factors as may be discussed from time to time. Although IDEX believes its

expectations and the information set forth in this presentation were based upon reasonable assumptions at the time when they were made,

it can give no assurance that those expectations will be achieved or that the actual results will be as described in this presentation. IDEX is not making any representation or warranty, expressed or implied, as to the accuracy, reliability, or completeness of the information in this presentation, and neither IDEX nor any of its directors, officers, or employees will have any liability to you or any other persons resulting

from your use of the information in this presentation. IDEX undertakes no obligation to publicly update or revise any forward-looking

information or statements in this presentation.

Introduction / Financial Summary

Introduction / Overview

• Continued execution on repositioning strategy from 2018
• TrustedBio™ extremely well-received
• • Driving industry partnerships and customer engagements
  • Mass production ready; no supply chain issues today
  • Shipping to multiple customers and early-adopter IDEMIA in Q1
  • We anticipate revenue growth through Q4 based on pipeline
• As adoption accelerates, we anticipate rapid growth of bookings
• • Post-pandemicacceleration of card pilots globally
  • Known bank programs scheduled for ramp in 2022
  • Potentially significant volumes from rapidly emerging DC/EP
  • • China initially, given aggressive target dates
    • ROW later, given >60 central bank studies underway

Q1 '21 Financial Summary

• Ongoing shift to product sales; sustained quarterly shipments of second-generation sensor and initial shipments of TrustedBio
• Expenses under control; payroll reflects targeted headcount growth and non-cash stock compensation
• Expenses of US registration and Norwegian offering drove expense growth for last two quarters
• February private placement should fund operations beyond point at which growth will be confirmed

Summary Profit & Loss Statement ($000)	Q1 2021	Q4 2020	Q3 2020	Q2 2020	Q1 2020
Product	$	623	$	593	$	246	$	121	$	53
Services		1		5		2		28		47
Total Revenue		624		598		248		149		100
Purchase, net of inventory change		220		178		45		32		19
Payroll expenses		5,101		5,206		4,275		3,515		4,677
Research and development expenses		608		(144)		930		1,069		40
Other operating expenses		1,713		2,157		1,370		1,218		1,191
Depreciation and amortization		454		439		430		422		429
Total Operating expenses		8,096		7,836		7,050		6,256		6,356
Loss from operations	$	(7,472)	$	(7,238)	$	(6,801)	$	(6,107)	$	(6,256)